333 related articles for article (PubMed ID: 16036178)
41. Improving diagnostic capability for HPV disease internationally within the NIH-NIAID Division of AIDS Clinical Trial Networks.
Godfrey CC; Michelow PM; Godard M; Sahasrabuddhe VV; Darden J; Firnhaber CS; Wetherall NT; Bremer J; Coombs RW; Wilkin T;
Am J Clin Pathol; 2013 Dec; 140(6):881-9. PubMed ID: 24225757
[TBL] [Abstract][Full Text] [Related]
42. [Screening of cervical cancer--update].
Dvorák V; Ondrus J
Ceska Gynekol; 2010 Feb; 75(1):65-8. PubMed ID: 20437841
[TBL] [Abstract][Full Text] [Related]
43. Impact of operational factors on HPV positivity rates in an HPV-based screening study in Colombia.
Robles C; Wiesner C; Martinez S; Salgado Y; Hernandez M; Lucas E; Lineros J; Romero P; Herrero R; Almonte M; Murillo R
Int J Gynaecol Obstet; 2018 Oct; 143(1):44-51. PubMed ID: 29944728
[TBL] [Abstract][Full Text] [Related]
44. Offering Self-Sampling Kits for HPV Testing to Reach Women Who Do Not Attend in the Regular Cervical Cancer Screening Program.
Arbyn M; Castle PE
Cancer Epidemiol Biomarkers Prev; 2015 May; 24(5):769-72. PubMed ID: 25713024
[TBL] [Abstract][Full Text] [Related]
45. The role of self-collection devices for cytology and human papillomavirus DNA testing in cervical cancer screening.
Bidus MA; Zahn CM; Maxwell GL; Rodriguez M; Elkas JC; Rose GS
Clin Obstet Gynecol; 2005 Mar; 48(1):127-32. PubMed ID: 15725865
[No Abstract] [Full Text] [Related]
46. Comparison between Urine and Cervical Samples for HPV DNA Detection and Typing in Young Women in Colombia.
Cómbita AL; Gheit T; González P; Puerto D; Murillo RH; Montoya L; Vorsters A; Van Keer S; Van Damme P; Tommasino M; Hernández-Suárez G; Sánchez L; Herrero R; Wiesner C
Cancer Prev Res (Phila); 2016 Sep; 9(9):766-71. PubMed ID: 27417431
[TBL] [Abstract][Full Text] [Related]
47. Liquid-based cervical cytology using ThinPrep technology: weighing the pros and cons in a cost-effectiveness analysis.
de Bekker-Grob EW; de Kok IM; Bulten J; van Rosmalen J; Vedder JE; Arbyn M; Klinkhamer PJ; Siebers AG; van Ballegooijen M
Cancer Causes Control; 2012 Aug; 23(8):1323-31. PubMed ID: 22706692
[TBL] [Abstract][Full Text] [Related]
48. External quality assessment for molecular detection of human papillomaviruses.
Fagan EJ; Moore C; Jenkins C; Rossouw A; Cubie HA; James VL
J Clin Virol; 2010 Aug; 48(4):251-4. PubMed ID: 20542463
[TBL] [Abstract][Full Text] [Related]
49. Cervical Cytology Specimen Stability in Surepath Preservative and Analytical Sensitivity for HPV Testing with the cobas and Hybrid Capture 2 Tests.
Tardif KD; Pyne MT; Malmberg E; Lunt TC; Schlaberg R
PLoS One; 2016; 11(2):e0149611. PubMed ID: 26905067
[TBL] [Abstract][Full Text] [Related]
50. Cervical screening in the UK and laboratory quality control in the context of the 2007 European guidelines.
Herbert A
Coll Antropol; 2007 Apr; 31 Suppl 2():41-6. PubMed ID: 17598504
[TBL] [Abstract][Full Text] [Related]
51. Development and evaluation of a PCR and mass spectroscopy (PCR-MS)-based method for quantitative, type-specific detection of human papillomavirus.
Patel DA; Shih YJ; Newton DW; Michael CW; Oeth PA; Kane MD; Opipari AW; Ruffin MT; Kalikin LM; Kurnit DM
J Virol Methods; 2009 Sep; 160(1-2):78-84. PubMed ID: 19410602
[TBL] [Abstract][Full Text] [Related]
52. Improving Laboratory Efficiency by Automation of Preanalytic Processing of ThinPrep Specimens for Real-Time PCR High-Risk HPV Testing.
Barbieri D; Venturoli S; Costa S; Landini MP
J Lab Autom; 2016 Jun; 21(3):432-8. PubMed ID: 25673634
[TBL] [Abstract][Full Text] [Related]
53. Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tools.
Kulmala SM; Syrjänen S; Shabalova I; Petrovichev N; Kozachenko V; Podistov J; Ivanchenko O; Zakharenko S; Nerovjna R; Kljukina L; Branovskaja M; Grunberga V; Juschenko A; Tosi P; Santopietro R; Syrjänen K
J Clin Microbiol; 2004 Jun; 42(6):2470-5. PubMed ID: 15184422
[TBL] [Abstract][Full Text] [Related]
54. Primary study on providing a basic system for uterine cervical screening in a developing country: analysis of acceptability of self-sampling in Lao PDR.
Yoshida T; Nishijima Y; Hando K; Vilayvong S; Arounlangsy P; Fukuda T
Asian Pac J Cancer Prev; 2013; 14(5):3029-35. PubMed ID: 23803074
[TBL] [Abstract][Full Text] [Related]
55. Quality assurance in human papillomavirus testing for primary cervical screening.
Cuschieri K; Fellner MD; Arroyo Mühr LS; Padalko E; Correa RM; Dillner J; Gultekin M; Picconi MA
Int J Gynecol Cancer; 2023 May; 33(5):802-811. PubMed ID: 36914171
[TBL] [Abstract][Full Text] [Related]
56. External quality assessment in gynaecological cytology: The Trent Region experience. The Trent Regional Gynaecological Pathology Quality Assurance Group for the National Health Service Cervical Screening Programme.
Slater DN; Hewer EM; Melling SE; Rice S
Cytopathology; 2002 Aug; 13(4):206-19. PubMed ID: 12269893
[TBL] [Abstract][Full Text] [Related]
57. The BAC recommended code of practice for cytology laboratories participating in the UK cervical screening programmes 2015 - an introduction.
Smart LM
Cytopathology; 2016 Feb; 27(1):5-7. PubMed ID: 26818037
[No Abstract] [Full Text] [Related]
58. The advent of human papillomavirus detection for cervical screening.
Morris BJ
Curr Opin Obstet Gynecol; 2019 Oct; 31(5):333-339. PubMed ID: 30946033
[TBL] [Abstract][Full Text] [Related]
59. External quality assessment program for human papillomaviruses DNA testing in Thailand.
Okada PA; Mitrat S; Rojanawiwat A
Pract Lab Med; 2024 Jan; 38():e00352. PubMed ID: 38292923
[TBL] [Abstract][Full Text] [Related]
60. [Assessment of HPV detection assays for use in cervical cancer screening programs].
Cañadas MP; Lloveras B; Lorincz A; Ejarque M; Font R; Bosch FX; de Sanjosé S
Salud Publica Mex; 2006; 48(5):373-8. PubMed ID: 17063820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
